EXPERTS have warned over hundreds rushed to hospital after using weight loss jabs – as half a million Brits now use the injections. Nearly 400 users have been hospitalised with serious, ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...
The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...
1d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.
The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback